Avobis Bio is pleased to announce that the primary analysis results of the phase II prospective, randomized STOMP-II clinical trial will be presented at ACG’s 2025 Annual Scientific Meeting. The STOMP-II trial is assessing AVB-114, Avobis Bio’s lead implantable cell therapy candidate, against the standard of care for the treatment of Crohn’s Disease perianal fistulas. More information on the study (NCT04847739) is available at www.clinicaltrials.gov.
Dr. David Schwartz, a STOMP-II investigator, Professor of Medicine in the Division of Gastroenterology, Hepatology and Nutrition, and Department of Medicine, and Director of the Inflammatory Bowel Disease Center at Vanderbilt University Medical Center, will present the results at Plenary Session 4B:IBD on Wednesday October 29, 2025. Please join us in Phoenix, AZ to hear the results of the STOMP-II clinical trial.